A Study of Ipatasertib in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy Participants
Status:
Completed
Trial end date:
2018-06-26
Target enrollment:
Participant gender:
Summary
This is a Phase 1 study evaluating the pharmacokinetics, tolerability and safety of a single
dose of ipatasertib in participants with mild, moderate or severe hepatic impairment compared
to healthy participants.